B. Riley Cuts Earnings Estimates for Cognition Therapeutics

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Equities research analysts at B. Riley reduced their FY2025 EPS estimates for Cognition Therapeutics in a research note issued to investors on Thursday, February 6th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings per share of ($0.87) for the year, down from their previous estimate of ($0.83). B. Riley has a “Buy” rating and a $1.50 price target on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share.

Other research analysts also recently issued research reports about the company. HC Wainwright increased their target price on Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a report on Thursday, December 19th. Brookline Capital Management upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a research note on Monday, January 27th. Finally, Chardan Capital restated a “buy” rating and set a $11.00 target price on shares of Cognition Therapeutics in a research report on Thursday, December 19th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $8.30.

Cognition Therapeutics Price Performance

NASDAQ CGTX opened at $0.60 on Monday. The stock has a market capitalization of $24.90 million, a price-to-earnings ratio of -0.62 and a beta of 0.96. Cognition Therapeutics has a 1-year low of $0.34 and a 1-year high of $2.95. The business’s fifty day moving average price is $0.65 and its 200-day moving average price is $0.62.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CGTX. SG Americas Securities LLC purchased a new position in Cognition Therapeutics during the fourth quarter valued at approximately $26,000. Virtu Financial LLC purchased a new position in shares of Cognition Therapeutics during the 3rd quarter valued at $27,000. Sigma Planning Corp boosted its holdings in Cognition Therapeutics by 14.6% in the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after buying an additional 25,050 shares during the period. Finally, BIOS Capital Management LP purchased a new stake in Cognition Therapeutics in the 4th quarter worth $4,208,000. 43.35% of the stock is currently owned by institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.